Harvard Bioscience Inc has a consensus price target of $6 based on the ratings of 3 analysts. The high is $7 issued by Benchmark on June 22, 2023. The low is $4 issued by Benchmark on March 10, 2023. The 3 most-recent analyst ratings were released by Benchmark, Benchmark, and Keybanc on June 22, 2023, April 26, 2023, and April 26, 2023, respectively. With an average price target of $7 between Benchmark, Benchmark, and Keybanc, there's an implied 134.11% upside for Harvard Bioscience Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Harvard Bioscience (NASDAQ:HBIO) was reported by Benchmark on June 22, 2023. The analyst firm set a price target for $7.00 expecting HBIO to rise to within 12 months (a possible 134.11% upside). 0 analyst firms have reported ratings in the last year.
The latest analyst rating for Harvard Bioscience (NASDAQ:HBIO) was provided by Benchmark, and Harvard Bioscience reiterated their speculative buy rating.
There is no last upgrade for Harvard Bioscience
There is no last downgrade for Harvard Bioscience.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harvard Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harvard Bioscience was filed on June 22, 2023 so you should expect the next rating to be made available sometime around June 22, 2024.
While ratings are subjective and will change, the latest Harvard Bioscience (HBIO) rating was a reiterated with a price target of $0.00 to $7.00. The current price Harvard Bioscience (HBIO) is trading at is $2.99, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.